PDF(Pubmed)
Abstract：
(1) Background: NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2) Methods: A single center retrospective study was conducted, on NF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3) Results: Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4) Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.
摘要：
（1）背景：NF2相关神经鞘瘤病，以双侧前庭神经鞘瘤的发展为特征，通常需要不同的治疗方法。贝伐单抗,虽然被广泛使用，对听力和肿瘤生长表现出不同的有效性。同时,（严重）不良事件经常报告。(2)方法:采用单中心回顾性研究,在2013年至2023年接受贝伐单抗治疗的NF2相关神经鞘瘤病患者中,目的是评估治疗相关结局和临床结局.感兴趣的结果包括听证会，放射学反应，症状,和不良事件。（3）结果：17例患者接受7.5mg/kg贝伐单抗治疗7.1个月。治疗后,40%的患者听力得到改善，53%,听力稳定,7%,听力损失。前庭神经鞘瘤消退发生率为31%，69%保持稳定。进一步的症状改善报告为41％，症状稳定47%，症状恶化12%。在29%的病例中观察到由于不良事件而停止治疗。高血压（82％）和疲劳（29％）是最常见的报告，没有发生4/5级毒性。(4)结论：支持先前的研究，贝伐单抗对听力有积极影响，肿瘤控制,和NF2相关神经鞘瘤病的症状，尽管有常见的不良事件。因此,有必要仔细考虑适当的管理策略。
